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Background: Intra-tumoral genetic and functional heterogeneity correlates with cancer clinical prognoses.
However, the mechanisms by which intra-tumoral heterogeneity impacts therapeutic outcome remain poorly
understood. RNA sequencing (RNA-seq) of single tumor cells can provide comprehensive information about gene
expression and single-nucleotide variations in individual tumor cells, which may allow for the translation of
heterogeneous tumor cell functional responses into customized anti-cancer treatments.
Results: We isolated 34 patient-derived xenograft (PDX) tumor cells from a lung adenocarcinoma patient tumor
xenograft. Individual tumor cells were subjected to single cell RNA-seq for gene expression profiling and expressed
mutation profiling. Fifty tumor-specific single-nucleotide variations, including KRASG12D, were observed to be
heterogeneous in individual PDX cells. Semi-supervised clustering, based on KRASG12D mutant expression and a risk
score representing expression of 69 lung adenocarcinoma-prognostic genes, classified PDX cells into four groups.
PDX cells that survived in vitro anti-cancer drug treatment displayed transcriptome signatures consistent with the
group characterized by KRASG12D and low risk score.
Conclusions: Single-cell RNA-seq on viable PDX cells identified a candidate tumor cell subgroup associated with
anti-cancer drug resistance. Thus, single-cell RNA-seq is a powerful approach for identifying unique tumor cell-
specific gene expression profiles which could facilitate the development of optimized clinical anti-cancer strategies.Background
Identification of somatic driver mutations in cancer has
led to the development of targeted therapeutics that
have improved the clinical outcomes of cancer patients
[1–3]. Lung adenocarcinoma (LUAD), the most common
histological subtype of non-small cell lung cancer [4], is
denoted by genetic alterations in the receptor tyrosine kin-
ase (RTK)-RAS-mitogen-activated protein kinase (MAPK)
pathway [2]. Companion diagnostics for hotspot muta-
tions of EGFR, KRAS, BRAF, and ALK, which are clinic-
ally associated with specific targeted cancer therapies, are
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is over 60 % [2], efforts to catalogue all the clinically
relevant genetic variations are still ongoing [6–9].
Moreover, drug resistance and disease recurrence after
anti-cancer treatments require more comprehensive
genomic analysis of individual LUADs [10, 11].
Although the individual cells in a tumor mass originate
from a common ancestor and share early tumor-initiating
genetic alterations, tumor cells frequently diverge and
show heterogeneity in growth [12–14], drug resistance
[15, 16], and metastatic potential [13, 14]. Intra-tumoral
heterogeneity results from mutation and clonal selection
dynamics during tumor growth [13, 14, 16], where indi-
vidual tumor cells accumulate cell-specific genetic
changes [12]. This genetic heterogeneity is significantly
associated with tumor progression and the treatment
outcomes of cancers [17, 18]. Therefore, monitoring
intra-tumoral heterogeneity at the single-cell levelle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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mechanisms after anti-cancer treatments [19] and guide
us in developing more sophisticated strategies to over-
come drug resistance.
Single-cell genome profiling technology provides the
highest-resolution analysis of intra-tumoral genetic het-
erogeneity [20–22]. Based on heterogeneity, we can
identify individual cells with specific genetic alterations
or genomic expression profiles that could be responsible
for treatment resistance. Therefore, correlating the geno-
type–phenotype relationship in genetically distinct single
cells can provide important new information for selecting
the most appropriate clinical intervention for targeting
heterogeneous LUADs [23]. For this purpose, patient-
derived xenograft (PDX) cells provide a genetically and
phenotypically accessible model for single cancer cell ana-
lyses of the heterogeneous histopathological, genetic, mo-
lecular, and functional characteristics of parental tumors
[24, 25]. Moreover, drug-resistant tumor cells can be se-










































































Fig. 1 Enrichment of cancer cells in the PDX. a Schematic representation o
propagated by xenograft transplantation in humanized immunocompromi
from xenograft tumors, and subjected to drug screening. b Estimated canc
by histopathological examination (striped bar), or estimated based on comp
c Estimated degree of normalized copy number changes in log2 ratio to m
indicated. Representative sites of copy number changes in LUAD are labele
the non-synonymous somatic mutations that overlap between Pt tumor an
of mutationsWe performed transcriptome profiling on single PDX
cells from a LUAD patient to elucidate the molecular
mechanisms and underlying genomic characteristics of
tumor cell resistance to anti-cancer drug treatments.
Single-cell transcriptome analysis uncovered heteroge-
neous behaviors of individual tumor cells and provided
new insights into drug resistance signatures that were
masked in bulk tumor analyses.
Results
Intra-tumoral genetic heterogeneity of LUAD PDX cells
Surgically removed LUAD tissue was propagated
through xenograft engraftments in mice (Fig. 1a). Viable
cancer cells were dissociated from the PDX tissue and
primarily cultured in vitro (Figure S1a in Additional file
1). Cultured PDX cells were genomically analyzed by
RNA sequencing (RNA-seq) and whole-exome sequen-
cing (WES). Although the tumor portion in the surgical
sample represented approximately 40 % of the excised
tissue volume (Figure S1b in Additional file 1), multiple&
re
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expression profiles [28] indicated that human cancer
cells were highly enriched (~100 %) in the PDX cells
(Fig. 1b). Overall, copy number alterations and variant
allele frequencies were increased in the PDX tumor,
compared with the surgical specimen (Fig. 1c, d). Some
mutations present in the patient tumor were lost in the
PDX, suggesting that our PDX model went through a se-
lective engraftment process [29]. The histologic charac-
teristics of the patient tumor were well preserved in the
PDX (Figure S1c in Additional file 1). The full profiles of
somatic mutations in the patient tumor and PDX cells
are listed in Additional file 2.
Tumor cell-enriched PDX cells (LC-PT-45) [30] were
further analyzed by single-cell RNA-seq using the Flui-
digm C1™ autoprep system with SMART-seq [31].
cDNAs from 34 individual PDX cells were successfully
amplified. Using 100-bp paired-end sequencing, we ob-
tained an average of 8.12 ± 2.34 million mapped reads
from the captured cells (Additional file 3). Overall,Fig. 2 Intra-tumoral heterogeneity of PDX cells. a Scatter plots of the avera
LC-PT-45-Re, n = 43) compared with those of the corresponding bulk cells
coefficients (Pearson r and Spearman r) for linear fit. TPM transcripts per mi
cells. Density plots were constructed with a kernel function fitting over the
expression in various numbers of single cells relative to the bulk cells was d
numbers with permutation (×1000). d Overlap ratio of expressed single-nu
constructed with a kernel function fitting over the histograms. e Overlap ratio
the bulk cells was calculated with a randomly selected given number of cells
range between the first and the third quartiles, error bars = 10th–90th percen85.63 % of reads mapped to the human reference gen-
ome, which was a lower percentage than is typical for
unamplified conventional RNA-seq, but comparable to
other single cell RNA-seq data [31, 32]. We also se-
quenced 50 single H358 human lung cancer cells as cell
line controls and obtained an 85.39 % mapping rate
(Additional file 3). Noticeably skewed coverage at the 3’
end of transcripts, which was inversely proportional to
the expression level, was observed in the single-cell
RNA-seq data (Additional file 4). The use of smaller ini-
tial RNA templates for amplification is known to in-
crease this bias [31].
Despite the sequencing bias in amplified RNAs, aver-
age gene expression in single cells correlated well with
expression in bulk cells, for both H358 and PDX cells
(Fig. 2a). The inter-correlation of total gene expression
among the 34 individual PDX cells showed wider distri-
bution compared with that in the 50 H358 cells (Fig. 2b),
indicating moderately higher transcriptome heterogen-
eity. The level of transcriptome heterogeneity was alsoge gene expression of single cells (H358, n = 50; LC-PT-45, n = 34;
(~1 × 105 cells). Black dotted lines are x = y lines with correlation
llion. b Inter-correlation (Pearson r) between gene expression in single
histograms. c Explanatory power (adjusted R-square) of gene
etermined by multiple regression analysis with randomly selected cell
cleotide variations (SNV) among single cells. Density plots were
of expressed SNVs of various numbers of single cells relative to that of
with permutation (×1000). For boxplots in (c) and (e), box = interquartile
tiles
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sized pools (n = 5, 15, 25, 34/35, 50; randomly selected
by permutation × 1000) of single cell transcriptomes to
the bulk sample (Fig. 2c). The modeling demonstrated
that five H358 or PDX individual cells represented
>70 % of the gene expression of the whole population.
When averaging increased numbers of cells, the single
cell data approximated the bulk up to 85 %, suggesting
that the single cell data are consistent with the bulk data
(Fig. 2c). We repeated the single cell isolation and RNA-
seq using 43 additional PDX cells and obtained compar-
able results that were highly correlated with the first
data set (Fig. 2; Figure S3a–f in Additional file 5, LC-PT-
45 and LC-PT-45-Re). Comparisons of gene expression
data for the 43 target genes (see Additional file 6 for the
gene list and Figure S3g in Additional file 5 for expres-
sion levels) between technical replicate RNA-seq sets
(Figure S3h left in Additional file 5) or between RNA-
seq and quantitative PCR (qPCR) analysis (Figure S3h
right in Additional file 5) also demonstrated statistically
significant correlation, comparable to that reported in a
previous publication [33].
Single-cell heterogeneity of expressed single-nucleotide
variants
To estimate tumor heterogeneity at the genetic mutation
level, we identified expressed single-nucleotide variants
(SNVs) using the single-cell RNA-seq and bulk WES
data (Figure S4a in Additional file 7). After removal of
potential false positive SNVs specifically found in RNA-
seq using the SNPiR package [34], higher overlap ratios
to bulk WES data were observed (Figure S4b middle
panels in Additional file 7). Selection of SNVs found in
both single cell RNA-seq and bulk WES data signifi-
cantly increased the overlap ratios to dbSNP137 (Figure
S4b right panels in Additional file 7). These filtered
SNVs of individual PDX cells showed relatively heteroge-
neous expression compared with those of H358 cells in
terms of the lower overlap ratios between single cells
(Fig. 2d). The union of SNVs from five PDX cells (ran-
domly selected by permutation × 1000) reflected 49 % of
the expressed SNVs in the whole population, whereas
those of five H358 cells represented 75 % (Fig. 2e). With
increased numbers of single cells, the coverage increased
up to 70 and 90 % for PDX cells (34 LC-PT-45 or 43
LC-PT-45-Re) and H358 cells, respectively.
After exclusion of germline variants by selecting only
somatic SNVs from bulk WES data, expression of 50
tumor-specific non-synonymous SNVs was analyzed in
individual PDX cells (Figure S4a in Additional file 7).
The 50 tumor-specific SNVs showed heterogeneous ex-
pression patterns in the individual PDX cells (Fig. 3a,
LC-PT-45) with numerous allele dropouts. For compari-
son, we plotted expression of lung cancer mutations inthe H358 cell line listed in COSMIC [35] (Figure S5a in
Additional file 8), which also showed variable expression
patterns with more uniform coverage (Figure S5b in
Additional file 8). For the PDX cells, we detected com-
parable mutation patterns and frequencies in the original
and replicate PDX analyses (Fig. 3a; Figure S3c, f in
Additional file 5, LC-PT-45 vs. LC-PT-45-Re RNA-seq).
The number of reads mapped to the human genome
reference were determined for individual cells to assure
sequencing quality (Fig. 3b). We also performed geno-
typing PCR on the LC-PT-45-Re samples in parallel,
which showed >70 % concordance with the RNA-seq re-
sults [Fig. 3a, LC-PT-45-Re (RNA-seq) vs. LC-PT-45-Re
(genotyping PCR), and Fig. 3c; Additional file 9]. To-
gether these data support reproducible cellular variance
in SNV expression. Nevertheless, no calls and discrepant
mutation calls between RNA-seq and genotyping PCR
demonstrate limitations of single cell RNA-seq, which
might have originated from allelic dropouts.
Among the genes with SNVs detected in PDX cells,
KRAS [1, 2], GAPVD1 [36], and JMJD1C [37] are func-
tionally related to the RTK-RAS-MAPK signaling path-
way. The hotspot KRASG12D mutation was detected in
27 out of 34 single PDX cells (79.4 %), or 33 out of 43
PDX replicates (76.7 %). To determine whether the
variable mutant allele expression was due to genetic
heterogeneity, we assessed the genotypes of 12 somatic
mutations at the single-cell DNA level with droplet
digital PCR (ddPCR; Figure S7a in Additional file 10).
When mutation rates were computed as variant allele
frequencies in bulk cells or as mutant single cell frac-
tions at both the DNA and RNA levels, they showed
overall correlation (Figure S7b in Additional file 10).
With respect to the KRAS mutation, all PDX cells (21
of 21) harbored the mutant allele in the single-cell
DNA analysis. Of note, copy number gains (Fig. 1c)
and mutant/wild-type ratios in KRAS (Figure S7c in
Additional file 10) suggest that variable copy numbers
of the mutant KRAS influenced the differential allele
expression. These data suggest that genetic heterogen-
eity contributes to variable mutant allele expression. In
addition, allele-biased expression may also contribute to
mutant allele expression heterogeneity. Given the im-
portance of oncogenic KRAS mutations, we defined two
subpopulations in the PDX based on the expressed
genotype: one with dominant KRASG12D expression, and
another without KRASG12D expression (KRASwild type (WT)
expression).
Identification of PDX cell subgroups
To further identify subclones with possible phenotypic
implications in the PDX cells, we utilized the expression
profiles of 69 genes related to the clinical prognosis of



























































































single cells with mutation
Hetero-


















































































Concordance of expressed SNVs identified




Fig. 3 Heterogeneous expression patterns of SNVs in PDX cells. a Expressed, tumor-specific, non-synonymous somatic mutations found in more
than three single cells of LC-PT-45. The replicate batch (LC-PT-45-Re) of single-cell RNA-seq and that of genotyping PCR are shown together. The
bar graphs at top left show mutation events per sample; the heat maps at bottom left show mutation profiles across samples; the bar graphs at
the right show normalized mutation fraction over total single cells (LC-PT-45, n = 34; LC-PT-45-Re, n = 43). b Mapping information from RNA-seq
for reads mapped to the human reference genome (hg19). The bar graph (left y-axis) shows the number of RNA-seq reads and the scatter plots
(right y-axis) with a connecting line show the unique mapping rate (uniquely mapped reads/input reads) in the same order as in (a). c Summary
of results for the matched samples and the validated targets between RNA-seq and genotyping PCR shown in (a). See Additional file 8 for
the details
Kim et al. Genome Biology  (2015) 16:127 Page 5 of 15markers to compute a risk score (RS) (Fig. 4a). A previ-
ous study [6] defined a high-RS population as those with
the top 40 % of RSs (normalized RS > 0). The prognostic
significance of the RS was validated in two independent
public datasets from The Cancer Genome Atlas and
from Korean LUAD patients (Additional file 12). More-
over, a higher RS was significantly associated with the
KRAS mutation in the LUAD patient population [6](Fig. 4b), which is consistent with a previously observed
correlation of the KRAS mutation with worse clinical
outcomes [5, 38].
Interestingly, individual PDX cells were calculated to
have a wide RS distribution (Fig. 4a). Eighteen out of the
34 PDX cells or 21 out of 43 of the replicate samples
were determined to be high-RS. We combined the repli-
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Fig. 4 Identification of PDX cell subclones using single-cell RNA-seq data. a Top: normalized RS. Middle: heatmaps of expression of 69 prognostic
markers. Bottom: KRAS mutation status of each patient (training set, n = 86) or single cell (LC-PT-45, n = 34; LC-PT-45-Re, n = 43). b Scatter plots
demonstrating the effect of the KRAS mutation on the RSs of LUAD patients and PDX single cells. Horizontal lines represent the mean. *P < 0.05;
**P < 0.01. c Semi-supervised clustering of single cells into four groups with estimated RS and KRAS mutant status. d Principal component analysis
of the genes discriminating the subgroups. Ellipsoids were generated with standard deviations around each group. e–h Comparative features
among the classified single cell subgroups. e KRAS gene expression (Log2 ratio of transcripts per million + 1). Gene set signature scores (computed
by gene set variation analysis) corresponding to the KRAS over-expression signature [39] (f), KRAS mutation signature [40] (g), and MAPK pathway
signature (gene sets from BioCarta) (h). For the boxplots in (e–h), boxes = the interquartile range between the first and third quartiles, and error
bars = 10th–90th percentiles
Kim et al. Genome Biology  (2015) 16:127 Page 6 of 15that PDX cells with KRASG12D expression tend to have a
higher RS (Fig. 4b). The finding is consistent with those
of LUAD patients in clinical studies [6]. Altogether,
semi-supervised clustering based on the expression of
the KRAS mutation and RS classified the PDX cells into
four groups: group 1, no KRASG12D (KRASWT)/low RS
(n = 3); group 2, KRASG12D/low RS (n = 25); group 3, no
KRASG12D (KRASWT)/high RS (n = 3); and group 4,
KRASG12D/high RS (n = 35) (Fig. 4c).
These four groups displayed characteristic gene ex-
pression profiles that likely reflect the different pheno-
types among individual PDX cells (Figure S9a in
Additional file 13). In particular, group 4 had enhanced
gene expression signatures associated with KRAS over-
expression and activation of the RAS-MAPK signaling
pathway [39, 40] (Fig. 4f, h), which correlated well with
KRAS mutational status. Group 4 PDX cells also showedsignificantly higher cell cycle gene mRNA expression
(Figure S9c in Additional file 13) [41]. In contrast, des-
pite having the KRAS mutation signature (Fig. 4g), group
2 cells had lower KRAS expression levels and KRAS
overexpression signatures (Fig. 4e, f ), lower RAS-MAPK
signaling pathway activation status (Fig. 4h), and re-
duced expression of cell cycle-related genes (Figure S9c
in Additional file 13).
The distinct gene expression signatures among the
four groups were visualized by a principal component
analysis (PCA) plot using genes exclusively expressed by
each group, with a criterion of at least a twofold change
in transcripts per million (TPM) ratio with statistical sig-
nificance (t-test P < 0.05; Fig. 4d). Although group 2 cells
showed a lower RAS-MAPK signaling pathway activa-
tion status, they had significantly upregulated expression
of ion channel transport pathway-related genes (Figure
Kim et al. Genome Biology  (2015) 16:127 Page 7 of 15S9b in Additional file 13), which has been implicated in
the drug resistance mechanism [10].
Phenotypic interpretation of PDX cell subgroups
The results above indicated that, in the PDX cell popula-
tion, there is a specific subgroup (group 4) that is pre-
dicted to be more aggressive than the other groups. This
subset is characterized by a high RS, KRAS mutation,
RAS-MAPK signaling pathway activation, and upregula-
tion of cell cycle-related genes. To determine whether
individual cells associate with tumor phenotypic aggres-
siveness, such as drug resistance, we screened the
in vitro sensitivity of the PDX cells against a panel of 25
anti-cancer agents used in non-small cell lung cancer
treatment (Additional file 14). The PDX cells were highly
sensitive to a variety of drug treatments, including doce-
taxel, and molecular pathway targeting agents. Among
the identified agents, we focused on the MEK1/2 inhibi-
tor selumetinib, and the phosphatidylinositide 3-kinase
(PI3K) inhibitors BKM120 and BEZ235 (PI3K/mTOR),
because of their potential clinical benefits [42, 43]. Other
cytotoxic drugs (e.g., carboplatin, and the Notch inhibi-
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Fig. 5 Interpretation of drug responses using single-cell signatures. a Dose
(cytotoxic compounds carboplatin and docetaxel; molecular targeting com
(top) and adjusted-expression of the 69 prognostic markers (middle) with K
cells. c–f Comparative features among the control and drug-treated PDX c
scores (computed by gene set variation analysis) corresponding to the KRA
and MAPK pathway signature (gene sets from BioCarta) (f). g Results from
control and drug-treated PDX cells. Ellipsoids correspond to the single cell
group 4, dark red), with the control and drug-treated PDX cells projected o
classification support vector machine type 1 (C-SVM classification) was appdocetaxel, BKM120, BEZ235, and selumetinib showed
tumoricidal effects, some PDX cells survived the three
days of treatment with these drugs when utilized at their
reported IC50.
When evaluated as a bulk population, PDX cells mani-
fested group 4-like characteristics with high RS and
KRASG12D. Ineffective treatments with carboplatin or
DAPT did not alter these properties of the group
(Fig. 5b–g). However, those PDX cells that survived the
docetaxel, BKM120, BEZ235, or selumetinib treatments
showed group 2-like gene expression signatures: low RS
(Fig. 5b), slight decrease in total KRAS expression levels
(Fig. 5c), down-regulation of gene expression signatures
associated with KRAS overexpression (Fig. 5d), preserva-
tion of the mutant KRASG12D expression signature
(Fig. 5e), and down-regulation of RAS-MAPK signaling
pathway activation (Fig. 5f ). Moreover, upregulation of
ion channel transport genes (Figure S9b in Additional
file 13) and downregulation of cell cycle-related genes
(Figure S9c in Additional file 13) were observed in these
treatment groups. The overall gene expression signature
represented by PCA confirmed the group 2 cell-like
properties of the drug-resistant PDX cells, in a supportB
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pounds DAPT, BKM120, BEZ235, and selumetinib). b Normalized RSs
RAS mutant expression (bottom) for the control and drug-treated PDX
ells. c KRAS gene expression (Log2 ratio of TPM + 1). Gene set signature
S over-expression signature [39] (d), KRAS mutation signature [40] (e),
the principal component (PC) analysis on single cells along with the
subgroups (group 1, light green; group 2, dark green; group 3, light red;
n the PC1-PC2 plane. Using single cell subgroups as a training set,
lied to a test set of the control and drug-treated PDX cells
Kim et al. Genome Biology  (2015) 16:127 Page 8 of 15vector machine (SVM) model (Fig. 5g). Altogether, these
results suggest that the drug-resistant population was
cell-cycle quiescent and with possibly higher transporter
activity for the anti-cancer drugs.
We further determined whether the group 2-like
population conveyed the low risk gene expression signa-
ture after anti-cancer drug treatment with selumetinib
(Figure S11a in Additional file 15). Interestingly, the low
RS of surviving PDX cells was gradually reverted to a
high RS after drug removal (Figure S11b in Additional
file 15). The KRAS over-expression signature (Fig. S11d
in Additional file 15) and MAPK pathway activation
(Figure S11f in Additional file 15) recovered as well. By
contrast, the level of total KRAS expression (Figure S11c
in Additional file 15) and mutational status (Figure S11e
in Additional file 15) were not altered by drug removal.
The possible mechanisms of the dynamic nature of these
gene expression signatures, such as epigenetic regulation
or recovery of heterogeneity by clonal proliferation, need
to be further elucidated.
Validation of analytical procedures in an independent
lung cancer PDX case
To validate our strategy of using single cell RNA-seq
data for subgroup identification, we used an independent
set of PDX cells derived from a lung cancer-brain metas-
tasis (LC-MBT-15) [30]. The LC-MBT-15 PDX harbors
an insertional mutation in EGFR exon 20, a well-known
driver mutation in LUAD conferring resistance to re-
versible EGFR inhibitors [44, 45]. Single cells from LC-
MBT-15 had less heterogeneous transcriptome and SNV
expression compared with the KRAS mutant PDX cells
(Figure S12a–e in Additional file 16), which might have
been caused by extensive clonal selection during serial
anti-cancer treatments before PDX establishment (see
the patient description in “Materials and methods”).
Nonetheless, the LC-MBT-15 single cells were still clus-
tered into two subgroups by RS, similar to the original
PDX case (Figure S12f, i in Additional file 16). In con-
trast to the KRASG12D mutation, the EGFR mutation was
modestly detected and showed no preferential expres-
sion in the high RS group (Figure S12g, h in Additional
file 16).
Drug screening on LC-MBT-15 cells was performed
using 28 lung cancer drugs (Additional file 17). LC-
MBT-15 cells were highly sensitive to the irreversible
EGFR/HER2 inhibitor afatinib and the c-Met inhibitor
tivantinib but were resistant to the reversible EGFR in-
hibitor erlotinib. When gene expression profiles for the
drug-resistant populations were analyzed 3 days later,
PCA of the single cells and application of a SVM model
for drug-treated populations revealed that the drug-
resistant populations shared the gene expression signa-
ture of the low RS group (Figure S12j, l in Additional file16). Interestingly, upregulation of ion channel transport
genes was also noted in the drug-resistant populations
(Figure S12k in Additional file 16), similar to the low
risk group single cells. These results are consistent with
the original LC-PT-45 PDX case, and further support
the observation that (1) single cell profiles of a popula-
tion reveal cells with drug-resistant signatures and (2)
the drug-resistant population may come from a subset
with higher transporter activity and low cell proliferation
activity.
Discussion
Single-cell genome analysis enables measurement of the
extent of intra-tumoral heterogeneity, which may pro-
vide clues for solving problems such as cancer recur-
rence, metastasis, and drug resistance [46]. Single-cell
RNA-seq can provide integrative information on both
gene expression and somatic SNVs, which makes it a
comprehensive tool to connect a cell’s genotype with its
expression profile and phenotype. We used tumor cell-
enriched LUAD PDX cells to define genomic signatures
of individual tumor cells, and then verified the applic-
ability of translating this information into biological can-
cer cell phenotypes such as drug responses.
When interpreting single cell RNA-seq data, the data
quality needs to be considered, because of the high mag-
nitude of amplification in the sequencing process. Se-
quence errors can be incorporated during the reverse
transcription, cDNA amplification, and library construc-
tion processes, causing false positive mutation calls.
RNA editing and monoallelic expression can also cause
discrepancies between SNV calls from RNA and DNA
sequencing. In this study, we focused on the RNA-seq
SNVs that were simultaneously detected by WES and
identified in more than three single cells. This approach
would minimize the probability of false positive SNV
calls. On the other hand, false negative SNV calls could
result from missing reads at the mutant position in both
DNA and RNA sequencing, which might be misinter-
preted as biological heterogeneity [47]. Various ap-
proaches such as Nuc-seq, which increases the starting
material by using G2/M phase cells, are reported to in-
crease the genome coverage up to 91 % for DNA
sequencing [48]. For the RNA-seq-based genotype ana-
lysis, mutations in rare transcripts are most prone to
the dropout events, suggesting that RNA-seq is suit-
able for genotyping highly expressed oncogenic driver
mutations.
Despite limitations in the accuracy of single-cell RNA-
seq, in this study we observed good correlations between
the merged single-cell data and the bulk cell data at both
the gene expression and expressed SNV levels. Once the
number of single cells exceeded 30, the averaged expres-
sion levels and consensus SNVs largely recapitulated the
Kim et al. Genome Biology  (2015) 16:127 Page 9 of 15data from bulk populations. Significant correlations were
also detected between replicate RNA-seq analyses and
with the PCR-based genotyping method. While these
concordant results and overall high expression level of
KRAS support the validity of the KRAS mutation calls in
RNA, 12–16 % of cells had insufficient RNA read counts
at the mutant position, resulting in ambiguous calls.
Downsizing sequencing data further increased the num-
ber of ambiguous calls (data not shown), indicating that
a sufficient number of reads is critical in the RNA-based
mutation analysis. This is in contrast to the gene expres-
sion analysis, which required only 0.5 million reads for
the transcriptome estimation [33].
We isolated single PDX cells from a KRAS-driven
tumor, which represents 25–33 % of LUADs [2, 3]. Com-
parison of the patient tumor and PDX cells revealed a
significant enrichment of KRAS mutant tumor areas in
the PDX, indicating that this PDX is a good model in
which to study KRAS-driven tumors. However, we ob-
served loss of some mutations as well as increased vari-
ant allele frequencies of many shared mutations and de
novo mutations, possibly resulting from the expansion
of subclones [29]. These subclones might be undergoing
proliferation due to clonal selection and adaptation in
the PDX, leading to a transient increase in genetic vari-
ation of the sample. In the longer term, the selection
would have diminished the level of tumor heterogeneity
originally present in the patient tumor. Therefore, use of
freshly isolated tumor cells is warranted for the accurate
estimation of tumor heterogeneity in future studies.
Because activating KRAS mutations are associated with
poor LUAD prognosis and due to the current lack of re-
liable targeting agents [5, 38], it is a clinical challenge to
find efficient treatment strategies for KRAS-driven can-
cers. According to the KRAS mutation status, the PDX
cells analyzed as a bulk population showed clinically un-
favorable genomic characteristics when the RS was cal-
culated from the signature of 69 prognostic genes [6].
However, single-cell RNA-seq of PDX cells revealed
intra-tumoral heterogeneity in terms of the KRAS mutant
and RS gene expression characteristics. Having individual
tumor cells that display intra-tumorally heterogeneous
molecular signatures that are prognostic in LUAD patients
is an interesting attribute. Similar findings were reported
in other single-cell or multi-regional studies in glioblast-
oma [32], in which single cells from the same tumor were
classified into multiple subtypes. Moreover, glioblastoma
patients with mixed subtype cells manifested worse prog-
noses [32], suggesting the prognostic value of defining
intra-tumoral heterogeneity.
The intra-tumoral heterogeneity might be driven by
DNA mutations as well as by epigenetic and regulatory
mechanisms. In this study we identified individual cells
with variable mutant KRAS gene expression and RSs.Both genetic and non-genetic factors likely contributed
to specify the subpopulations. The gene expression sig-
natures might be driven by genomic profiles, including
KRAS, and other environmental factors, including the
drug treatment. The gradual reversion of drug-resistant
signatures after drug withdrawal (Additional file 15) sug-
gests that non-genetic regulatory mechanisms could be
involved in the specification. To devise effective anti-
cancer treatment strategies, we need to understand the
underlying mechanisms whereby transcriptome hetero-
geneity is maintained in the tumor.
According to the prognostic value of the activating
KRAS mutation and RS, PDX cells with KRASG12D ex-
pression and high RS would be expected to be drug re-
sistant. Moreover, as a whole population, the PDX cells
had a high KRASG12D variant allele frequency and high
RS that masked the no KRASG12D (KRASWT) and/or
low RS cell types. The use of tumoricidal anti-cancer
drugs with different mechanisms of action (cytotoxic
and targeting specific signaling pathways) dramatically
changed the gene expression features of the PDX cells
in this study from KRASG12D plus high RS to KRASG12D
plus low RS. The result was counterintuitive, since
high RS is significantly associated with worse prognosis
of LUAD patients. However, in an independent PDX
case, cells with a low RS also survived in vitro anti-
cancer treatments, supporting the validity of the unex-
pected results.
The unexpected results indicate that (1) tumor cells
with activated KRAS signatures were drug targets, but
the KRAS mutation itself was not a target, and (2) the
actual tumor population responsible for drug resistance
might be masked by dominant genomic characteristics
within a bulk population. In this study, the cells that sur-
vived the effective treatments retained the KRAS muta-
tion but seemed to stay in a dormant state without
activating KRAS signaling. Interestingly, the molecular
signatures of this group indicated upregulation of genes
involved in the ion channel transport and P-type
ATPases, which might play key roles in drug resistance
[10]. Whether this potentially drug-resistant population
is indeed a pre-existing tumor subclone or dynamically
changes gene expression signatures in response to drug
treatments needs to be addressed by future studies.
Conclusions
This study demonstrates that gene expression and
somatic SNVs of single tumor cells could be retrieved
simultaneously by single-cell RNA-seq. Furthermore,
the genomic data obtained could be used to elucidate
potentially drug-resistant subclones and to generate
hypotheses on the molecular mechanisms of treatment
resistance that are masked in the whole cancer cell
population.
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Patient samples and PDX cells
This study was carried out in accordance with the prin-
ciples of the Declaration of Helsinki, and approved by
The Samsung Medical Center (Seoul, Korea) Institu-
tional Review Board (no. 2010-04-004). Participants in
this study gave written informed consent for research
and publication of the results. Surgical specimens were
acquired from a 60-year-old male patient who under-
went surgical resection of a 37-mm irregular primary
lung lesion in the right middle lobe (LC-PT-45), and
from a 57-year-old female patient who underwent surgi-
cal resection of a metachronous brain metastasis
(LC-MBT-15). The LC-PT-45 tumor was taken in a
treatment-naïve status whereas the LC-MBT-15 tumor
was taken after standard chemotherapy and erlotinib
treatments. Pathologic examination of the primary tu-
mors revealed a poorly differentiated lung adenocarcin-
oma based on the World Health Organization criteria
[49]. The PDX cells were isolated and cultured in vitro
as described previously [24, 30, 50]. Briefly, surgically
removed tumor tissues were directly injected into the
subrenal space of 6–8-week-old humanized immuno-
compromised female NOG (NOD/Shi- SCID/IL-2Rγ-null)
mice (Orient Bio, Seongnam, Korea). Xenograft tumors
were taken from the mice for PDX cell culture and vali-
dated by short tandem repeat DNA fingerprinting as hav-
ing been derived from the original tumor. We used PDX
cells at fewer than three in vitro passages for single-cell
RNA-seq and drug screening. Animal care and handling
was performed according to the National Institute of
Health Guide for the Care and Use of Laboratory Animals
(NIH publication no.80-23, revised 1978).
Drug screening with PDX cells
Dissociated PDX cells were cultured in neurobasal
media-A supplemented with N2 (×1/2; Life Technologies,
Carlsbad, CA, USA), B27 (×1/2; GIBCO, San Diego, CA,
USA), basic fibroblast growth factor (bFGF; 25 ng/mL;
R&D Systems, Minneapolis, MN, USA), epidermal growth
factor (EGF; 25 ng/mL; R&D Systems), neuregulin 1
(NRG; 10 ng/mL; R&D Systems), and insulin-like growth
factor 1(IGF1; 100 ng/mL; R&D Systems). The cells grown
in these serum-free sphere culture conditions were seeded
in 384-well plates (500 cells/well), and treated with a drug
library (Selleck, Houston, TX, USA). The drug library was
composed of targeted agents and cytotoxic chemothera-
peutics, which were included in the clinical guideline or
current clinical trial for the treatment of non-small cell
lung cancer. After 3 days of incubation at 37 °C in a 5 %
CO2 humidified incubator, cell viability was analyzed
using an adenosine triphosphate monitoring system
based on firefly luciferase (ATPlite™ 1step; PerkinElmer,
Waltham, CA, USA). Test concentrations for each drugwere empirically determined to produce a clinically rele-
vant spectrum of drug activity. Dose response curves
and corresponding half maximal (50 %) inhibitory con-
centration values (IC50) were calculated using the S+
Chip Analyzer (Samsung Electro-Mechanics, Suwon,
Korea) [51].
WES and data processing
Genomic DNA was extracted from PDX cells using the
QIAamp® DNA Mini kit (Qiagen, Hilden, Germany) or
QIAamp DNA Blood Maxi Kit (Qiagen). Exomes were
captured using the SureSelect XT Human All Exon V5
kit (Agilent Technologies, Inc., Santa Clara, CA, USA).
The sequencing library was constructed and analyzed by
the HiSeq 2000 or 2500 systems (Illumina, San Diego,
CA, USA) using the 100-bp paired-end mode of the
TruSeq Rapid PE Cluster kit and TruSeq Rapid SBS kit
(Illumina). Mean target coverage for exome data was
153.4 ± 26.99 × .
Exome-sequencing reads were aligned to the hg19 ref-
erence genome using BWA-0.7.10 [52]. Putative duplica-
tions were marked by Picard-1.93 software [53]. Sites
potentially harboring small insertions or deletions were
realigned, and SNVs were called by applying GATK-3.2
[54] ‘HaplotypeCaller’ with known variant sites identified
from phase I of the 1000 Genomes Project [55] and
dbSNP-137 [56], using default option parameters. Then,
called variants were evaluated to obtain highly accurate
call sets through a two-stage processing step of ‘Varian-
tRecalibrator’ and ‘ApplyRecalibration’, using default
option parameters. To detect somatic mutations with
increased sensitivity both in lower and higher allele fre-
quencies [57], we used the caller programs of MuTect-
1.1.5 [58] and VarScan2 [59].
Estimation of copy number variation from WES was
performed using the ExomeCNV software package [26]
in default quantification mode. Circular binary segmen-
tation was applied to determine the neighboring regions
of DNA that exhibited a statistically significant differ-
ence in copy number. The output was also applied to
infer tumor purity using AbsCNseq [27].
Isolation of single cells and RNA-seq
We used the C1™ Single-Cell Auto Prep System (Fluidigm,
San Francisco, CA, USA) with the SMARTer kit (Clon-
tech, Mountain View, CA, USA). For the original ex-
periment, 44 cells were captured as a single isolate on
a C1 array chip for mRNA sequencing (17–25 μm) as
determined by microscopic examination, and 34 passed
the required criteria for cDNA quantity and quality as
measured with a Qubit® 2.0 Fluorometer (Life Technolo-
gies) and 2100 Bioanalyzer (Agilent). RNA from bulk cell
samples was also amplified using a SMARTer kit with
10 ng of starting material. Libraries were generated using
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quenced on the HiSeq 2500 using the 100-bp paired-end
mode of the TruSeq Rapid PE Cluster kit and TruSeq
Rapid SBS kit.
RNA-seq data processing
RNA-seq reads were aligned to the human genome ref-
erence (hg19) together with splice junction information
of each sample using the two-pass default mode of
STAR_2.4.0d [60]. Gene expression was quantified by
implementing RSEM v.1.2.18 [61] in default mode with
Genecode v.19 [62] annotation, and calculated as the sum
of isoform expression. Pre-processing steps for RNA-seq
reads before calling variants were optimized by deduplica-
tion, splitting reads into exon segments, hard-clipping any
sequences overhanging the intronic regions, realigning
reads and recalibration using GATK-3.2 [54]. Then, vari-
ants were called by ‘HaplotypeCaller’ mode with option pa-
rameters of (−R hg19.fa –genotyping_mode DISCOVERY
-recoverDanglingHeads -dontUseSoftClippedBases –dbsnp
dbsnp_137.hg19.vcf -stand_emit_conf 20 -stand_call_conf
20 -nct 4). Highly accurate variants were filtered by
applying ‘VariantFiltration’ (option parameters: −F
hg19.fa -window 35 -cluster 3 -filterName FS -filter
“FS > 30.0” -filterName QD -filter “QD < 2.0” \). After
removal of variant call quality Q < 20, further filtering
was applied to SNVs that were considered to be po-
tential false positives in RNA-seq by SNPiR [34]. We
regarded only those SNVs which overlapped with
WES as true positives. The overall process of calling
and filtering the variants is summarized in Figure
S4a in Additional file 7.
Computing RS using multivariate markers
RSs were regression coefficients calculated by a linear
combination of the expression values of the prognosis
markers using a training set [6] of LUAD patients. Prog-
nosis markers were also derived from the previous re-
port [6] that classified LUAD patients according to gene
expression profiles of the suggested markers, and 69
genes were ultimately chosen by overlapping our data
sets after gene filtering of zero expression across all sin-
gle cells. These filtered genes (Additional file 11) were
validated as prognosis markers with independent LUAD
datasets from The Cancer Genome Atlas [2] and from a
Korean LUAD cohort [63]. Batch effects on gene expres-
sion between independent datasets were removed by
means of ComBat [64]. Regression coefficients and P
values of the training set were estimated using univariate
Cox proportional hazards regression modeling and or-
dered by P values. To partition patient samples into high-
and low-RS-based groups upon computation of response
score, we applied a 60th percentile cutoff as described in
Beer et al. [6]. Survival analysis was performed using the RSurvival package [65] and validated through Kaplan-Meier
survival curves with log-rank testing (training set, P =
1.04 × 10−6; validation set, P = 9.25 × 10−3) (Figure S8b in
Additional file 12).
To classify the control and drug-treated PDX cells into
semi-supervised clustered single cells (LC-PT-45, Fig. 4;
LC-MBT-15, Additional file 16: Figure S12), a classifica-
tion SVM type 1 (C-SVM classification) model was ap-
plied using the R package e1071 [66].
Gene set signature activation analysis
To characterize gene expression features of a subgroup
compared with the other groups among the classified
single cells, we utilized the GSEA-P program with de-
fault mode searching for significantly enriched gene set
signatures [67]. Applied gene sets were derived from the
three major curated pathway databases of KEGG, REAC-
TOME, and BIOCARTA in MSigDB v.4.0 [68]. To esti-
mate the gene set activation status of a single sample,
gene set variation analysis [69] was applied in default
mode.
Validating gene expression and expressed SNVs at the
RNA level by qPCR
Gene expression and expressed SNVs were assessed by
qPCR or SNP type PCR across single cells using a Bio-
mark HD system (Fluidigm). cDNAs obtained from the
C1 array for mRNA sequencing chip were subjected to
specific target amplification following the manufacturer’s
recommendations. For the gene expression qPCR, Delta
Gene Assay (Fluidigm) with EvaGreen second generation
dsDNA binding dye was performed for gene sets se-
lected from the RS genes (Additional file 6). To compare
correlations between RNA-seq and qPCR platforms for
the selected 43 gene expression, mean fold change over
median expression was calculated as in the previous
study [33]. Validation of expressed SNVs at the RNA
level was carried out using a SNP Type Assay (Fluidigm)
with locus-specific primer sequences. Primers were de-
signed using D3™ software (Fluidigm), and sequences are
available in Additional file 6.
Validating genomic variants at the DNA level by ddPCR
PDX cells were labeled with 6-carboxyfluorescein succi-
nimidyl ester (Life Technologies) and sorted into single
cells using a FACSAria™ III flow cytometer (BD Biosci-
ences, CA, USA). Wells with a single green fluorescence
signal were manually inspected and selected for amplifi-
cation of genomic DNA with a GenomiPhi V2 DNA
Amplification Kit (GE Healthcare, Little Chalfont, UK).
The mutant alleles were detected using ddPCR Super-
mix for Probes reagents (Bio-Rad, Hercules, CA, USA)
implemented using a QX200 ddPCR system, following
the manufacturer’s protocols. The negative signal of
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numbers of wild-type or mutation alleles in droplets
were estimated in a Poisson distribution. Variant allele
frequency was calculated by counting copies of mutation
alleles over the total number of detected alleles. We
regarded genotypes of detected variants as homozygous
when the variant allele frequency was higher than 90 %.
Sequences of the primers used in ddPCR are available in
Additional file 6.
Statistical analysis of single-cell gene expression
Linear regression was applied to scatter plots of the av-
eraged single cells over the pooled-cell samples in Fig. 2a
with zero intercepts. The inter-correlation distribution
between single cells was calculated as Pearson’s and
Spearman’s correlation coefficients, and plotted as a
density plot with a kernel function fitting over the histo-
grams (Fig. 2b). Multiple regression analysis estimated
how many single cells hypothetically accounted for the
pooled cell fraction. Single-cell samples were randomly
chosen with the given number and the adjusted R2
(Fig. 2c) and the overlap ratio (Fig. 2e) were determined
1000 times with permutation. The differences in normal-
ized RS, gene expression, and gene set activation score
between single-cell subgroups were tested using two-
tailed Student’s t-tests.
Data access
The data reported in this paper have been deposited at
the Samsung Genome Institute (SGI) data repository
[70] and at the NCBI Gene Expression Omnibus (GEO)
under accession number GSE69405.
Additional files
Additional file 1: Figure S1. Propagation of LUAD tumor cells in the
xenograft model. a A summarized depiction of the experimental process
of tumor engraftment from a LUAD patient into mice. b Histological
examination by a licensed pathologist determined the tumor area
(dotted lines) in formalin-fixed, paraffin-embedded (FFPE) samples of a
patient tumor. c Evaluation of propagation of LUAD from a patient and
in mice by immunohistochemistry analysis, using lung adenocarcinoma
cell-specific markers (TTF-1 and Napsin A) and a lung squamous cell
carcinoma-specific marker (CK 5/6). Scale bar, 100 μm (b, c). H&E
hematoxylin and eosin.
Additional file 2: Table S1. Somatic mutations identified in PDX cells.
Additional file 3: Table S2. Summary of mapping information for
RNA-seq samples.
Additional file 4: Figure S2. Coverage plots of transcripts based on
expression level. Expression levels of the transcripts were rank-ordered
and classified in each sample. Top: top 1000 transcripts. Middle: 500
transcripts above and 500 transcripts below the median, rank-ordered.
Bottom: bottom 1000 transcripts. Coverage ratio was normalized to the
maximal degree of coverage in each sample. Standard deviation across
samples is depicted as thinner vertical lines over thicker curves.
Additional file 5: Figure S3. Evaluation of batch effects using a
technical replicate set. a Principal component analysis for total data sets
of single cells used in this study. b, c Interrelation between single cellsfrom LC-PT-45 and LC-PT-45-Re, a technical replicate set, in gene
expression (measured by Pearson r) (b), and in expressed SNVs (measured
by overlap ratio) (c). Unsupervised hierarchical clustering trees were
constructed by applying Euclidean distance. d–f Reciprocal relations
between single cells and bulk cells from the other batch set. d Scatter
plots depicting average gene expression of single cells and bulk cells.
Black dotted lines are x = y lines with correlation coefficients (Pearson r
and Spearman r) for linear fit. e Explanatory power (adjusted R-square) of
gene expression of various numbers of single cells relative to the bulk
cells was determined by multiple regression analysis using randomly
selected cell numbers with permutation (×1000). f Overlap ratio of
expressed SNVs of various single-cell numbers relative to that of the bulk
cells was calculated with a randomly selected given number of cells with
permutation (×1000). For the boxplots in (e) and (f), box = interquartile
range (IQR) between the first and the third quartiles, error bars = 10th–90th
percentiles. g Distribution of mean expression across single cell RNA-seq
data for the total genes (main graph) and for the genes used in qPCR (inset,
n = 43). h Evaluation of gene expression variation across single cells
between two batch sets of RNA-seq (left), and between the two
technical platforms of RNA-seq and qPCR (right). For parallel comparison
(left and right panels), 43 target gene probes were selected for validation.
Black dotted lines are x = y lines with correlation coefficients (Pearson r and
Spearman r) for linear fit.
Additional file 6: Table S4. Information on primers used in qPCR
(expression and genotyping) and ddPCR.
Additional file 7: Figure S4. Detection and filtering of variants in
single-cell RNA-seq data. a Schematic overview of data processing for the
discovery of expressed variants. See “Materials and methods” for details. b
Comparative evaluation of the detection processes for genomic variants
in RNA-seq, following filtering steps marked in (a).
Additional file 8: Figure S5. Expressed genotypes of SNVs in H358
cells. a Top left: bar graph of mutation events per sample. Bottom left:
heat map of mutation profiles across samples. Right: bar graph of
normalized mutation fraction over total single cells (n = 50). b Mapping
information from RNA-seq reads to a human reference genome (hg19).
Vertical bar plots of the number of RNA-seq reads (left y-axis) and scatter
plots with a connecting line for the unique mapping rate (uniquely
mapped reads/input reads, right y-axis) are in the same order as in (a).
Additional file 9: Figure S6. Summary heatmap identifying
concordance between RNA-seq and genotyping PCR across matched
single cells. Top left: bar graph of concordance events per sample. Bottom
left: heat map of concordance profiles across samples. Right: bar graph of
normalized concordance fraction over total single cells (LC-PT-45-Re,
n = 43).
Additional file 10: Figure S7. Comparison of various platforms for
detecting mutant single cell fractions and variant allele frequencies of
bulk cells. a The summarized results of ddPCR for selected SNVs at the
DNA level. Top left: bar graph of mutation events per sample. Bottom left:
heat map of mutation profiles across samples. Right: bar graph of
normalized mutation fraction over total single cells (LC-PT-45, n = 21). b
Multidimensional scatter plots of the comparative fraction of SNVs across
various platforms. Black dotted lines are x = y lines with correlation
coefficients (Pearson r and Spearman r) for linear fit. c The variant allele
frequency (VAF) of KRASG12D across single cells separately measured for
DNA (by ddPCR) and RNA (by RNA-seq).
Additional file 11: Table S3. Prognostic genes used for computing risk
scores.
Additional file 12: Figure S8. Application of risk scores to patient
survival in LUAD cohorts. a Strategy to classify single cells according to
prognostic marker expression. b Kaplan-Meier curves of overall survival of
patients in two independent LUAD cohorts and of recurrence-free
survival of patients in a Korean LUAD cohort, according to the estimated
risk scores (log-rank test).
Additional file 13: Figure S9. Distinct gene expression signatures
among the classified single cell subgroups along with the drug treatment
groups. a Expression heatmap discriminating single cells into subgroups
classified as in Fig. 4c. bREACTOME-defined ion channel transport is
significantly activated in group 2 compared with the other groups, as
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determined using the nominal P values. ES enrichment score; NES
normalized enrichment score. Gene set activation signatures were
estimated for the control and drug-treated PDX cells by gene set
variation analysis. c Gene expression signature for the cell cycle was
estimated by gene set variation analysis. The gene set for the cell cycle
signature was obtained from REACTOME.
Additional file 14: Figure S10. Procedure and the results of drug
screening for LC-PT-45. a The overall process from PDX cell preparation
to drug screening. b Summarized list of drugs used in the screening, their
known targets, and calculated IC50s. The six anti-cancer compounds used
in this study are indicated: †cytotoxic compounds carboplatin and
docetaxel; *molecular targeting compounds DAPT, BKM120, BEZ235, and
selumetinib.
Additional file 15: Figure S11. Assessment of phenotypic reversibility
for selumetinib-mediated gene expression signatures. a The experimental
design to examine the change of gene expression under selumetinib.
LC-PT-45 PDX cells were serially collected before and after 3-day exposure
to 1 μM selumetinib, and on 3 days (R3) and 7 days (R7) after the wash-
out of the drug. b Normalized RSs (top) and adjusted-expression of the
69 prognostic markers (middle) with KRAS mutant expression (bottom) for
the mock- and selumetinib-treated PDX cells. c–f Comparative features
among the mock- and selumetinib-treated PDX cells. c KRAS gene
expression (Log2 ratio of TPM + 1). Gene set signature scores (computed
by gene set variation analysis) corresponding to the KRAS overexpression
signature [39] (d), KRAS mutation signature [40] (e), and MAPK pathway
signature (gene sets from BioCarta) (f).
Additional file 16: Figure S12. Validation of analytical procedures on
an additional PDX, LC-MBT-15. a A scatter plot of the average gene
expression of single cells (n = 49) and that of the corresponding bulk cells
(~1 × 105 cells). Black dotted line is the x = y line with correlation
coefficients (Pearson r and Spearman r) for linear fit. b Inter-correlation
(Pearson r) between gene expression of single cells. Density plots were
constructed with a kernel function fitting over the histograms. c Explanatory
power (adjusted R-square) of gene expression of various numbers of single
cells relative to the bulk cells was determined by multiple regression analysis
using randomly selected cell numbers with permutation (×1000). d Overlap
ratio of expressed SNVs among single cells. Density plots were constructed
with a kernel function fitting over the histograms. e Overlap ratio of
expressed SNVs of various single-cell numbers relative to that of the bulk
cells was calculated with a randomly selected given number of cells with
permutation (×1000). For the boxplot, box = interquartile range (IQR)
between the first and the third quartiles, error bars = 10th–90th percentiles.
f Top: bar graph of normalized RS. Middle: heatmap of expression of 69
prognostic markers. Bottom: bar graph of KRAS and EGFR mutation status of
single cells. g Scatter plots demonstrating the lack of impact of the EGFR
mutation on RSs of LC-MBT-15 single cells. Horizontal lines represent the
mean. h EGFR gene expression (Log2 ratio of TPM+ 1). For the boxplots in
(g, h), box = IQR between the first and the third quartiles, error bars = 10th–
90th percentiles. i Graphical illustration of principal component analysis of the
genes discriminating between the low-RS and high-RS subgroups. Ellipsoids
were generated with standard deviations around each subgroup. j Top: bar
graph of normalized RSs. Middle: heatmap of adjusted-expression of the 69
prognostic markers. Bottom: KRAS and EGFR mutation status for the control
and drug-treated PDX cells. k Gene set activation signatures were
estimated for single cells (left) and the control and drug-treated PDX
cells (right) by gene set variation analysis. Gene expression signatures for
ion channel transport and cell cycle were from REACTOME. l Results
from the principal component (PC) analysis on single cells along with
the control and drug-treated PDX cells. Ellipsoids corresponding to the
single cell subgroups [low-RS (green), high-RS (red)], with the control
and drug-treated PDX cells projected on the PC1-PC2 plane. Using single
cell subgroups as a training set, a C-SVM classification was applied to a
test set of the control and drug-treated PDX cells.
Additional file 17: Figure S13 The results of drug screening for
LC-MBT-15. Summarized list of drugs used in the screening, their known
targets, and calculated IC50s. The six anti-cancer compounds used in this
study are indicated: †cytotoxic compounds carboplatin and docetaxel;
*molecular targeting compounds afatinib, DAPT, erlotinib, and tivantinib).Abbreviations
bp: base pair; ddPCR: droplet digital PCR; LUAD: lung adenocarcinoma;
MAPK: mitogen-activated protein kinase; PCA: principal component analysis;
PCR: polymerase chain reaction; PDX: patient-derived xenograft;
PI3K: phosphatidylinositide 3-kinase; qPCR: quantitative PCR; RNA-seq: RNA
sequencing; RS: risk score; RTK: receptor tyrosine kinase; SNV: single-nucleotide
variation; SVM: support vector machine; TPM: transcripts per million;
WES: whole-exome sequencing; WT: wild type.
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